
Diane M Simeone

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/68131/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Identification of Pancreatic Cancer Stem Cells. Cancer Research, 2007, 67, 1030-1037.	0.9	3,017
2	Tumor-Associated Macrophages Produce Interleukin 6 and Signal via STAT3 to Promote Expansion of Human Hepatocellular Carcinoma Stem Cells. Gastroenterology, 2014, 147, 1393-1404.	1.3	529
3	Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. Gut, 2020, 69, 7-17.	12.1	357
4	c-Met Is a Marker of Pancreatic Cancer Stem Cells and Therapeutic Target. Gastroenterology, 2011, 141, 2218-2227.e5.	1.3	333
5	Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer. Gut, 2017, 66, 124-136.	12.1	269
6	Pilot Clinical Trial of Hedgehog Pathway Inhibitor GDC-0449 (Vismodegib) in Combination with Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma. Clinical Cancer Research, 2014, 20, 5937-5945.	7.0	255
7	Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma. Ca-A Cancer Journal for Clinicians, 2020, 70, 375-403.	329.8	237
8	SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models. Cancer Discovery, 2018, 8, 1237-1249.	9.4	216
9	Expansion of CTCs from early stage lung cancer patients using a microfluidic co-culture model. Oncotarget, 2014, 5, 12383-12397.	1.8	175
10	GM-CSF Mediates Mesenchymal–Epithelial Cross-talk in Pancreatic Cancer. Cancer Discovery, 2016, 6, 886-899.	9.4	156
11	The Notch Pathway Is Important in Maintaining the Cancer Stem Cell Population in Pancreatic Cancer. PLoS ONE, 2014, 9, e91983.	2.5	138
12	CEACAM1, a Novel Serum Biomarker for Pancreatic Cancer. Pancreas, 2007, 34, 436-443.	1.1	137
13	Bmi1 Enhances Tumorigenicity and Cancer Stem Cell Function in Pancreatic Adenocarcinoma. PLoS ONE, 2013, 8, e55820.	2.5	94
14	High-Throughput Microfluidic Labyrinth for the Label-free Isolation of Circulating Tumor Cells. Cell Systems, 2017, 5, 295-304.e4.	6.2	88
15	Metabolic Regulation of Redox Balance in Cancer. Cancers, 2019, 11, 955.	3.7	80
16	A Pilot Study of Diffusion-Weighted MRI in Patients Undergoing Neoadjuvant Chemoradiation for Pancreatic Cancer. Translational Oncology, 2014, 7, 644-649.	3.7	63
17	Opportunities and Challenges for Pancreatic Circulating TumorÂCells. Gastroenterology, 2016, 151, 412-426.	1.3	60
18	HNF1A is a novel oncogene that regulates human pancreatic cancer stem cell properties. ELife, 2018, 7, .	6.0	51

DIANE M SIMEONE

#	Article	IF	CITATIONS
19	The biological underpinnings of therapeutic resistance in pancreatic cancer. Genes and Development, 2021, 35, 940-962.	5.9	51
20	Synergistic targeting and resistance to PARP inhibition in DNA damage repair-deficient pancreatic cancer. Gut, 2021, 70, 743-760.	12.1	49
21	Proteins associated with pancreatic cancer survival in patients with resectable pancreatic ductal adenocarcinoma. Laboratory Investigation, 2015, 95, 43-55.	3.7	44
22	New Labyrinth Microfluidic Device Detects Circulating Tumor Cells Expressing Cancer Stem Cell Marker and Circulating Tumor Microemboli in Hepatocellular Carcinoma. Scientific Reports, 2019, 9, 18575.	3.3	38
23	An academic career in global surgery: a position paper from the Society of University Surgeons Committee on Academic Global Surgery. Surgery, 2018, 163, 954-960.	1.9	34
24	Vitamin D Receptor Activation and Photodynamic Priming Enables Durable Low-dose Chemotherapy. Molecular Cancer Therapeutics, 2020, 19, 1308-1319.	4.1	33
25	A phase I trial of cabozantinib and gemcitabine in advanced pancreatic cancer. Investigational New Drugs, 2016, 34, 733-739.	2.6	31
26	Low dose photodynamic therapy harmonizes with radiation therapy to induce beneficial effects on pancreatic heterocellular spheroids. Oncotarget, 2019, 10, 2625-2643.	1.8	31
27	Dominant role of CDKN2B/p15INK4B of 9p21.3 tumor suppressor hub in inhibition of cell-cycle and glycolysis. Nature Communications, 2021, 12, 2047.	12.8	30
28	Bmi1 is required for the initiation of pancreatic cancer through an Ink4a-independent mechanism. Carcinogenesis, 2015, 36, 730-738.	2.8	29
29	Microfluidic continuum sorting of sub-populations of tumor cells via surface antibody expression levels. Lab on A Chip, 2017, 17, 1349-1358.	6.0	26
30	Protein Kinase A Modulates Transforming Growth Factor-β Signaling through a Direct Interaction with Smad4 Protein. Journal of Biological Chemistry, 2013, 288, 8737-8749.	3.4	24
31	Characterizing human pancreatic cancer precursor using quantitative tissue optical spectroscopy. Biomedical Optics Express, 2013, 4, 2828.	2.9	23
32	Localized Pancreatic Cancer: Multidisciplinary Management. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e217-e226.	3.8	23
33	ATDC binds to KEAP1 to drive NRF2-mediated tumorigenesis and chemoresistance in pancreatic cancer. Genes and Development, 2021, 35, 218-233.	5.9	23
34	Clinical evaluation, imaging studies, indications for cytologic study and preprocedural requirements for duct brushing studies and pancreatic fine-needle aspiration: The Papanicolaou Society of Cytopathology Guidelines. CytoJournal, 2014, 11, 1.	1.7	22
35	Islet hypertrophy following pancreatic disruption of Smad4 signaling. American Journal of Physiology - Endocrinology and Metabolism, 2006, 291, E1305-E1316.	3.5	20
36	ATDC is required for the initiation of KRAS-induced pancreatic tumorigenesis. Genes and Development, 2019, 33, 641-655.	5.9	20

DIANE M SIMEONE

#	Article	IF	CITATIONS
37	ATDC (Ataxia Telangiectasia Group D Complementing) Promotes Radioresistance through an Interaction with the RNF8 Ubiquitin Ligase. Journal of Biological Chemistry, 2015, 290, 27146-27157.	3.4	17
38	ATDC mediates a TP63-regulated basal cancer invasive program. Oncogene, 2019, 38, 3340-3354.	5.9	17
39	In vivo optical spectroscopy for improved detection of pancreatic adenocarcinoma: a feasibility study. Biomedical Optics Express, 2014, 5, 9.	2.9	15
40	SSAT/AGA/ASGE State of the Art Conference on Cystic Neoplasms of the Pancreas. Journal of Gastrointestinal Surgery, 2008, 12, 1475-1477.	1.7	14
41	Profiling Heterogeneous Circulating Tumor Cells (CTC) Populations in Pancreatic Cancer Using a Serial Microfluidic CTC Carpet Chip. Advanced Biology, 2018, 2, 1800228.	3.0	13
42	A Phase I/II Open-Label Multicenter Single-Arm Study of FABLOx (Metronomic 5-Fluorouracil) Tj ETQq0 0 0 rgBT /0 Pancreatic Cancer. Journal of Pancreatic Cancer, 2019, 5, 35-42.	Overlock 1 0.9	.0 Tf 50 547 10
43	Post-brushing and fine-needle aspiration biopsy follow-up and treatment options for patients with pancreatobiliary lesions: The Papanicolaou Society of Cytopathology Guidelines. CytoJournal, 2014, 11, 40.	1.7	5
44	Pancreatic Microtumors: A Novel 3D Ex Vivo Testing Platform. Methods in Molecular Biology, 2019, 1882, 73-80.	0.9	5
45	Needle-compatible miniaturized optoelectronic sensor for pancreatic cancer detection. Science Advances, 2020, 6, .	10.3	5
46	Cancer surveillance awareness and practice among families at increased risk for pancreatic adenocarcinoma. Cancer, 2021, 127, 2271-2278.	4.1	5
47	Proteome heterogeneity and malignancy detection in pancreatic cyst fluids. Clinical and Translational Medicine, 2021, 11, e506.	4.0	2
48	Next generation sequencing (NGS) to identify relapsed gastrointestinal (GI) solid tumor patients with human leukocyte antigen (HLA) loss of heterozygosity (LOH) for future logic-gated CAR T therapy to reduce on target off tumor toxicity Journal of Clinical Oncology, 2022, 40, 190-190.	1.6	2
49	Impact of changing guidelines on genetic testing and surveillance recommendations in a contemporary cohort of breast cancer survivors with family history of pancreatic cancer. Scientific Reports, 2021, 11, 12491.	3.3	1
50	BASECAMP-1: Leveraging human leukocyte antigen (HLA) loss of heterozygosity (LOH) in solid tumors by next-generation sequencing (NGS) to identify patients with relapsed solid tumor for future logic-gated Tmod CAR T-cell therapy Journal of Clinical Oncology, 2022, 40, TPS2676-TPS2676.	1.6	0